Sibeprenlimab decreases 24-hour UACR in IgA nephropathy: ENVISION Trial Results.

Published Date: 05 Nov 2023

ASN Kidney Week 2023 saw the presentation of the ENVISION trial results, which offer the most recent information on the role of sibeprenlimab in the treatment of IgA nephropathy while the nephrology community waits for the outcomes of the trial's ongoing phase 3 development.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot